In the UK, point of care genomic testing for mtRNR1 has been initiated prior to aminoglycoside use in neonatal sepsis, and NICE is expected to shortly release guidelines recommending CYP2C19 testing to guide choice of therapeutics after stoke.23 The gene discussed is CYP2C19; the disease is Neonatal sepsis.